Cell No. : Cell Name
RCB1280 : TGBC50TKB
update : 2024/09/02
|
Comment | 3 cell lines from different metastases were established from the same patient. See TGBC51TKB. Application consideration |
Comment from the depositor | |
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
Todoroki, T. & Ohno, T.
|
Originator |
Ohno, Tadao & Yasugi Tomoko
|
Year of deposit |
1996
|
Another name |
YaKa
|
Animal |
_human
< Mammals
|
Genus |
Homo
|
Species |
sapiens
|
Race |
Japanese
|
Gender |
Male
|
Age at sampling |
52 years
|
Tissue |
papilla vater, liver meta
|
Metastatic ability |
Yes
|
Metastatic tissue |
lymph node,peritoneu
|
Classification |
cancer
|
Year of origin |
1996
|
|
Lifespan |
infinite
|
Morphology |
epithelial-like
|
Cellosaurus(Expasy) |
CVCL_H693
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
Culture medium |
|
DMEM (low glucose) + 10% FBS
|
Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
SC frequency |
|
Subculture : once/10-14 days, Medium Renewal : 2 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma/Acholeplasma |
|
(-)
|
Virus (HBV) |
|
(-)
|
Virus (HCV) |
|
(-)
|
Isozyme |
|
LD, NP
|
Chromosome mode |
|
66-72(50) : 66(1),67(10),68(8),69(10),70(13),71(6)/
|
STR(human) |
|
OK
|
Images |
deposit info | lot info |
|
|
Reference information |
Reference |
0
|
User's Publication |
2
|
User's Publication |
3738
Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Cancer Chemother Pharmacol.
2019
83(4):659-671
PubMed ID: 30659304
DOI: 10.1007/s00280-019-03768-8
|
9603
Lai ZW, Bolm L, Fuellgraf H, Biniossek ML, Makowiec F, Hopt UT, Werner M, Keck T, Bausch D, Sorio C, Scarpa A, Schilling O, Bronsert P, Wellner UF.
Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses.
BMC Cancer
2016
16:195
PubMed ID: 26951071
DOI: 10.1186/s12885-016-2193-5
|